SIGLEC1 and COVID-19: Taken together, the larger effect size between COVID-19 and healthy controls as well as the higher expression levels in monocytes suggested that IFI27 and SIGLEC1 is a monocyte-specific biomarker with slightly different property in response to viral infection.